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S U M M A R Y
Objective: To assess the impact of Clostridium difﬁcile infection (CDI) on hospital resources and costs in
Spain and Italy.
Methods: CDI data were collected from institutions in Spain and Italy. Each patient was matched with
two randomly selected uninfected controls in the same institution. Patient outcomes were assessed for
the ﬁrst and second episodes of CDI and for patients aged 65 and >65 years. The impact of CDI on
hospital length of stay (LOS) was used to calculate CDI-attributable costs. A multivariate analysis using
duration of stay as the continuous outcome variable assessed the independent effect of CDI on hospital
costs and LOS.
Results: LOS attributable to CDI ranged from 7.6–19.0 days in adults and was 5.0 days in children; the
increases were greater in adults in Italy than in Spain. Attributable costs per adult patient ranged from
s4396 in Madrid to s14 023 in Rome, with the majority of the cost being due to hospitalization. For
children, the total attributable cost was s3545/patient.
Conclusions: These data show that the burden of CDI is considerable in Spain and Italy. Treatments that
can reduce LOS, disease severity, and recurrence rates, as well as effective infection control measures to
prevent transmission, have the potential to reduce the burden of CDI.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Clostridium difﬁcile infection (CDI), which is caused by an
anaerobic, Gram-positive, spore-forming bacillus, is the leading
cause of infectious diarrhoea in hospitalized adult patients, causing
infections ranging from mild diarrhoea to pseudomembranous
colitis.1–3 The most important risk factor for CDI is prior or ongoing
antimicrobial therapy, which can disrupt the normal intestinal
ﬂora and allow C. difﬁcile to colonize the gut.1–3 Other risk factors
include chemotherapy, solid organ and bone marrow transplanta-
tion, and chronic treatment with proton pump inhibitors.2,4* Corresponding author. Tel.: +34 911 917 413.
E-mail address: aasensiov@salud.madrid.org (A. Asensio).
http://dx.doi.org/10.1016/j.ijid.2015.05.013
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Speciﬁc patient groups are also considered to be at risk, e.g.
elderly, chronically ill, and immunocompromised patients.2,3
However, CDI is becoming an increasingly common cause of
community-acquired diarrhoea in low-risk populations, such as
children, healthy adults, and pregnant women.1,4
Although viral infections (rotavirus, norovirus) remain the
leading causes of diarrhoea in the paediatric population, CDI is also
considered to be an increasingly common cause of hospital-
acquired diarrhoea and an emerging cause of community-acquired
diarrhoea in children.2,5 In contrast to adults, no relationship with
antibiotic exposure or comorbid conditions has been observed in
children with community-acquired CDI.2–4,6
Many reports have shown that the incidence and severity of CDI
are increasing and that it is associated with increasing morbidity
and mortality; however, most studies have been performed inciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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conducted by the European Centre for Disease Prevention and
Control in 2008 showed that the incidence of CDI differs between
countries; the reported rates in Italy and Spain were 3.6 and
4.3 episodes per 10 000 patient-days, respectively.10 Although the
study had a uniform design with a ﬁxed 3-month follow-up, some
studies have suggested that the diagnostic testing approach used
causes variations in estimates of the incidence of CDI.11–13
However, country-speciﬁc studies in Spain and Italy indicate that
the prevalence of CDI is increasing: between 1999 and 2007, the
prevalence rate increased from 3.9–12.2 per 100 000 population in
Spain,14 with more recent data indicating that rates remain high
(13.4–22.5 per 100 000) and suggesting that CDI is under-
diagnosed due to the diagnostic methods used;15,16 in Italy, the
incidence of CDI in ﬁve large hospitals in Rome increased
signiﬁcantly (p < 0.001) over the 6-year period between
2006 and 2011 (from 0.3–2.3 episodes per 1000 patient-days).17
The resource burden of CDI is considerable. A retrospective
cohort study of infected (n = 38) and matched non-infected (n = 76)
patients conducted during an outbreak of nosocomial CDI in Spain
in 2006, demonstrated that patients who developed CDI were
exposed to more antibiotics, had higher mortality, and were
hospitalized for longer.18 A retrospective cross-sectional study in
Italy showed that CDI is associated with considerable costs in an
Italian hospital setting, with length of stay (LOS) being the most
important factor in determining costs,19 although this study had
methodological limitations. CDI in hospitalized children has been
shown to increase the risk of death, extend hospital LOS, and
increase hospital costs.20 The general conclusion that CDI has a
considerable resource impact is supported by a report showing
that CDI is associated with a signiﬁcant increase in attributable
healthcare costs.21 The increasing economic burden of CDI in
healthcare facilities in Europe has been demonstrated, with
incremental costs of infection in the range of s1857–s4266.22
However, this study included only limited data from Spain and no
information from Italy.22
As evidence regarding the impact of CDI on healthcare
resources in southern Europe is generally scarce, the aim of this
study was to analyse data on the burden of CDI in terms of hospital
resources and costs, and in particular CDI-attributable LOS, in
Spain and Italy.
2. Methods
2.1. Patient selection
Patients with CDI were diagnosed based on a positive C. difﬁcile
toxin immunoassay or positive culture for toxigenic C. difﬁcile and
signs and symptoms compatible with CDI (three or more unformed
stools within 24 h). All patients with CDI diagnosed at the Hospital
Universitario Puerta de Hierro, Majadahonda, Madrid, Spain
(tertiary care referral hospital with a large solid organ transplan-
tation programme and approximately 650 beds; period of data
collection January 2011–November 2013), Hospital del Mar,
Universitat Auto`noma de Barcelona, Barcelona, Spain (tertiary
care hospital with approximately 400 beds, including 18 in an
intensive care unit; data collected February–November 2011), and
Department of Translational Medical Science, University of Naples
‘‘Federico II’’, Naples, Italy (tertiary care hospital, including
specialist paediatric medical and surgical departments with
50 beds; data collected 2006–2012) were included. Patients for
inclusion in the study were selected randomly at the National
Institute for Infectious Diseases ‘‘L. Spallanzani’’, Rome, Italy
(tertiary care hospital with medical, surgical, and diagnostics
departments and approximately 200 beds; data collected January
2011–August 2013).2.2. Data extraction protocol
A protocol for data extraction from patient records was
developed and used to collect data. For each institution, data for
hospital-onset cases of CDI (infected cohort) and uninfected
control patients (non-infected cohort) were collected. Hospital-
onset was deﬁned as >48 h after admission or <4 weeks after
discharge from a healthcare facility (Naples only).
2.3. Matched cohort design
Each patient in the infected cohort was matched with two
randomly selected uninfected control patients in the same
institution. Patients were matched by ward and period of hospital
admission (15 days). For each patient in the infected and non-
infected cohorts, data regarding main disease diagnosis at hospital
admission, demographics, hospital department in which they were
treated, and other factors potentially associated to LOS were
collected. This matched cohort design was used to overcome the
problem of how to assign hospital LOS data directly to C. difﬁcile.
For the patients in the infected cohort, the index day was
deﬁned as the day of hospital stay when the patient was diagnosed
with CDI. For those in the non-infected cohort, patients were
selected randomly from those whose duration of stay was at least
as long as that from the date of admission to the index day for the
case with which they were matched. For these patients, the index
day was deﬁned as the same day of hospitalization as the index day
of the case with which they were matched.
2.4. Data collected
To control for severity of illness before CDI infection, data
required for the calculation of a modiﬁed Acute Physiology and
Chronic Health Evaluation III (APACHE) score23 were collected for
all patients 48 h before the index day. The modiﬁed APACHE score
did not include blood pH, pulmonary arterial oxygen saturation,
pulmonary arterial gradient, urine output, or scoring for neuro-
logical abnormalities, because these data were not available for all
patients in the study, particularly those not in the intensive care
unit (ICU). To control for underlying disease, the Charlson
comorbidity index was calculated using patient medical history.24
It should be noted that while data for these two measures were
collected for the paediatric patients, the validity of the measures
for paediatric patients is uncertain.
To control for prognosis of primary disease, the McCabe–
Jackson index was estimated.25 Finally, information about previous
antibiotic use was collected from the date of hospital admission to
date of infection for cases, and from the date of hospital admission
to the index day for controls.
The following data on CDI were collected: duration of diarrhoea,
treatment for CDI, hospital LOS (including ICU and isolation days),
whether sigmoidoscopy/colonoscopy was performed, and clinical
outcomes, including cure, mortality at 30 days, attributable
mortality, and recurrence. Based on the guidelines available at
the time that patients were diagnosed,26 recurrence was deﬁned as
a second episode of CDI based on clinical symptoms, a positive
diagnostic test for C. difﬁcile, or both, occurring within 2–8 weeks of
the index case and within the hospital stay.
2.5. Treatment protocols
In Spain, adult patients with mild-to-moderate CDI received
metronidazole 250 mg every 6 h for 10 days, whereas in Italy they
received metronidazole 500 mg every 8 h for 10 days. Severe
infections were treated using oral vancomycin 125–500 mg every
6 h for 10 days. Recurrences were treated using oral vancomycin
A. Asensio et al. / International Journal of Infectious Diseases 36 (2015) e31–e38 e33125–500 mg every 6 h for 10 days or ﬁdaxomicin 200 mg twice
daily for 10 days.
Paediatric patients with mild-to-moderate CDI were usually
treated with metronidazole 125 or 250 mg every 8 h according to
body weight for 7–14 days; patients with severe or recurrent
infections received vancomycin 10 mg/kg/dose every 6 h (to a
maximum of 1500 mg/day).
2.6. Costs
In Spain, the costs of metronidazole and vancomycin were
s1.08 (20 units of 250 mg) and s3.45 (1 unit of 125 mg),
respectively.27 The daily cost of a hospital in-patient stay was
s443.59 and the daily cost of ICU was s1156.07.27 An estimated
average daily cost of stay was calculated by comparing the total
number of days patients spent in the ICU with the total days spent
in hospital and calculating a weighted average cost.
In Italy, costs of s708.54 and s1214.64 were used for daily
adult hospitalization and ICU costs. These are based on the value
reported by Magalini et al.19 inﬂated to 2013 values using the
Italian Consumer Price Index.28 The costs of metronidazole and
vancomycin were s1.30 (per g) and s4.60 (per g), respectively.
The cost of hospitalization per day in children was s708.54, also
based on the value reported by Magalini et al.19
2.7. Analyses performed
In the adult population, the following analyses were performed.
First, patient outcomes were assessed both for the ﬁrst and second
episodes of CDI and by therapy used. The impact of CDI on hospital
LOS, including time in the ICU, was also calculated. Furthermore,
the number of isolation days (contact precautions) was assessed.
Each of these outcomes was analysed both in the overall
population and in patients aged 65 and >65 years. These
measures were used to calculate CDI attributable costs.Table 1
Patient and disease characteristics
Institution
Madrid Barc
Characteristic Infected Non-infected Infe
Adult/paediatric Adult Adult Adu
n 94 150 12 
Mean age, years (range) 70.4
(21–98)
65.7
(20–100)
55.3
(21–
Male (%) 50.0 62.0 58.3
Prior antibiotic use (%) 74.5 75.0
Admission service (%)
Medical 71 67 75 
Surgical 23 28 8 
ICU 4 5 17 
Other 2 1 0 
Mean serum albumin, g/l (range) 3.05
(0.3–4.0)
3.42
(2.0–5.2)
2.70
(1.4
McCabe–Jackson disease classiﬁcation (%)
Non-fatal 59.6 62.7 66.7
Rapidly fatal 17.0 12.7 0.0 
Ultimately fatal 23.4 24.7 33.3
Mean Charlson comorbidity index score (range)c 6.3
(0–14)
5.33
(0–12)
2.8
(0–9
Mean APACHE score (range)d 34.7
(0–68)
28.8
(0–73)
9.3
(2–1
ICU, intensive care unit; NR, not reported.
a All paediatric patients were admitted to the paediatric department.
b For paediatric patients, disease was classiﬁed as non-fatal or ultimately fatal only.
c Used to assess the risk of 10-year mortality based on the scoring of 19 medical cond
associated with a higher risk of death.
d APACHE III is a severity-of-disease classiﬁcation system used in ICUs; scoring rangFor the paediatric patients, the type and outcome of therapy was
captured for the ﬁrst and subsequent episodes of CDI. The impact
of CDI on hospital LOS, isolation days, and costs was analysed.
2.8. Statistical analyses
To analyse the independent effect of CDI on hospital costs and
LOS, a multivariate analysis using a continuous outcome variable of
duration of stay (post-infection duration of hospitalization for the
infected cohort and duration of hospitalization after the index day
for the non-infected cohort) was performed. Potential confounding
variables were taken into account: modiﬁed APACHE III score
(incorporates age), Charlson comorbidity index score, and
McCabe–Jackson disease classiﬁcation.
Median rather than mean values were used for the outcome
measures to reduce the inﬂuence of extreme or outlier values. This
approach was considered more appropriate than using mean
values, which have been used in other studies. By not adjusting for
skewed data, the use of mean values tends to overestimate
difference. The alternative – log transformation of data – tends to
underestimate difference.
Median regression analysis using the qreg function in the
statistical program Stata version 12 (StataCorp., College Station,
TX, USA) was regarded as valid.
3. Results
3.1. Patient and disease characteristics
In total, data were collected for 232 adult infected patients and
426 matched non-infected patients in Madrid (n = 94), Barcelona
(n = 12), and Rome (n = 126). Nineteen patients in Madrid had
community-onset CDI and were not matched to non-infected
patients. In addition, data for 19 paediatric infected patients and
38 matched non-infected patients were also collected in Naples.elona Rome Naples
cted Non-infected Infected Non-infected Infected Non-infected
lt Adult Adult Adult Paediatric Paediatric
24 126 252 19 38
80)
53.8
(25–80)
65.8
(19–95)
55.2
(18–101)
9.0
(0.8–17)
11.1
(1–18)
 58.3 57.1 54.4 68.4 36.8
 91.3 43.4
75 89 77 –a –a
8 6 20
17 5 3
0 0 0
–4.2)
3.13
(1.2–4.0)
2.86
(0.1–4.3)
4.1
(2.8–4.9)
4.46
(3.5–4.9)
 70.8 82.5 94.1 100.0 36.8
4.2 4.0 1.6 0
 25.0 13.5 4.4 0 63.2b
)
2.7
(0–10)
6.0
(0–18)
3.7
(0–13)
NR NR
6)
11.5
(0–35)
NR NR NR NR
itions, which are weighted to provide a score in the range 0–45; higher scores are
es from 0–299, with higher scores associated with a higher risk of death.
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Differences in age were observed, most likely because the
matching criteria used did not specify age, and probably
contributed to the difference in Charlson index scores observed
in Italy. Data on antibiotic use prior to the diagnosis of CDI are
shown in the Supplementary Material (Online Resources 1 and 2).
3.2. First episode of CDI
3.2.1. Adults
Data regarding the disease characteristics of the initial episode
of CDI, its treatment, and the outcomes of treatment for the overall
population and patients aged 65 and >65 years (Madrid and
Rome only) are shown in Table 2 (data for patients who did not
have a recurrence and those who had a recurrence are shown in the
Supplementary Material (Online Resources 3 and 4)). It should be
noted that a proportion of patients received non-oral therapy:
26 patients in Madrid (intravenous metronidazole n = 19, intra-
colonic vancomycin n = 2, both n = 5), four in Barcelona (intrave-
nous metronidazole n = 3, intracolonic vancomycin n = 1), and
16 in Rome (all intravenous metronidazole). Disease character-
istics were generally similar for adult patients at the different sites,
both for the overall population and the patients aged >65 years,
although the incidence of ulceration and colonic wall thickening
appeared to be lower in Italy than in either Madrid or Barcelona.
However, this could be due to differences in the proportions of
patients who underwent computed tomography in different
institutions. Finally, while outcomes in Spain were generally
similar for patients aged >65 and 65 years, patients aged >65
years had worse outcomes than those aged 65 years in Rome.
3.2.2. Children
Data regarding the disease characteristics of the initial episode
of CDI, its treatment, and the outcomes of treatment for paediatricTable 2
Initial CDI, treatment, and outcomes
Institution
Madrid 
All 65 years >65 year
n 94 33 61 
Mean duration of diarrhoea, days (range) 10.1 (1–48) 8.7 (2–33) 10.9 (1–4
Diarrhoea contains blood (%) 15.0 15.6 14.7 
Fever (%) 15.0 18.8 13.1 
Ileus (%) 3.2 3.1 3.3 
Leukocyte count 15  109/l (%) 31.2 37.5 27.9 
Serum creatinine increase >50% (%) 24.7 12.5 31.1 
Sigmoidoscopy/colonoscopy (%) 7.5 9.4 6.6 
Pseudomembranes (%) 8.6 9.4 8.2 
Ulceration (%) 3.2 3.1 3.3 
Colonic wall thickening (%) 14.0 21.9 9.8 
Pericolonic fat (%) 4.3 3.1 4.9 
Treatment, n (%)b
Metronidazole, oral 79 (84.0) 27 (81.8) 53 (86.9)
Metronidazole, intravenous 24 (25.5) 7 (22.6) 17 (25.0)
Vancomycin, oral 13 (13.8) 5 (15.2) 8 (13.1)
Vancomycin, intracolonic 7 (7.5) 4 (12.1) 3 (4.9) 
Outcomes (%)c
Cure 75 (80.6) 26 (81.3) 49 (80.3)
Failure 13 (14.0) 5 (15.6) 8 (13.1)
30-day mortality 14 (15.1) 5 (15.6) 9 (14.8)
1-year mortality 19 (20.4) 6 (18.8) 13 (21.3)
Attributable mortality 4 (4.3) 1 (3.1) 3 (4.9) 
Recurrenced 7 (7.5) 2 (6.3) 5 (8.2) 
CDI, Clostridium difﬁcile infection.
a Not analysed by age due to small patient numbers.
b Patients may have received more than one antibiotic.
c Outcomes data not available for one patient in Madrid and four patients in Rome.
d Deﬁned as a second episode of CDI occurring within 2–8 weeks of the index case patients in Naples are shown in Table 2. Disease characteristics
were generally comparable to those in adults, but the incidence of
ulceration and colonic wall thickening was higher than that in the
adult patients in Rome. In contrast to adult patients, the ﬁrst
episode of CDI in children was exclusively treated with oral
therapy. No deaths due to the ﬁrst episode of CDI were reported.
3.3. CDI recurrence
A total of 34 adult patients (12.5%) and two paediatric patients
(10.5%) experienced a ﬁrst recurrence of CDI. Three of the 34 adult
patients and one of the two paediatric patients had a further
recurrence. Although ﬁdaxomicin was included in the treatment
protocols for recurrent CDI in Spain and Italy, no patient was treated
with this agent. Two deaths occurred in patients with a ﬁrst
recurrence, both attributable to CDI and both occurring in Rome. No
deaths were reported in this patient group in the other centres,
whether attributable to CDI or not. No CDI-attributable mortality
was reported in patients with a second CDI recurrence. No statistical
analysis of potential differences in outcomes was performed due to
the small sample size of the recurrent CDI groups.
3.4. Attributable hospital LOS
Data for hospital LOS, including days spent in isolation and the
ICU, and hospital LOS attributable to CDI are shown in Tables 3–
5. LOS attributable to CDI was generally similar in adults aged 65
and >65 years. However, the data suggest that the LOS attributable
to CDI was longer in adults with CDI in Italy than in adults with CDI
in Spain. LOS attributable to CDI in children was shorter than in
adults in both Spain and Italy.
In Madrid, the LOS attributable to CDI was shorter for the ﬁrst
episode (6.4 days) than for the ﬁrst recurrence (45 days)
(Tables 4 and 5). This was also the case in Rome, although theBarcelonaa Rome Naples
s All All 65 years >65 years Paediatric
12 126 54 72 19
8) 11.8 (2–25) 12.9 (2–50) 11.5 (2–50) 14.0 (2–42) 7.8 (0–30)
16.7 6.3 7.4 5.6 36.8
8.3 18.2 22.2 15.3 21.0
8.3 2.4 1.9 2.8 0.0
25.0 32.5 24.1 70.8 36.8
0.0 21.4 11.1 29.2 0.0
8.3 7.1 5.6 8.3 15.8
8.3 0.0 0.0 0.0 0.0
0.0 3.2 1.8 4.2 10.5
33.3 7.1 5.6 8.3 5.3
0.0 0.8 0.0 1.4 0.0
 10 (83.3) 83 (65.9) 39 (72.2) 44 (61.1) 10 (52.6)
 3 (25.0) 16 (12.7) 3 (5.6) 13 (18.1) 0
 1 (8.3) 36 (28.6) 12 (22.2) 24 (33.3) 5 (26.3)
1 (8.3) 0 0 0 0
 12 (100.0) 79 (64.8) 42 (80.8) 37 (52.9) 17 (89.5)
 0 (0.0) 5 (4.1) 3 (5.8) 2 (2.9) 1 (5.3)
 1 (8.3) 18 (14.8) 4 (7.7) 14 (20.0) 0 (0.0)
 1 (8.3) 19 (15.6) 4 (7.7) 15 (21.4) 0 (0.0)
0 (0.0) 7 (5.7) 1 (1.9) 6 (8.6) 0 (0.0)
2 (16.7) 25 (20.5) 6 (11.5) 19 (27.1) 2 (10.5)
within hospital stay.
Table 3
Hospital LOS for all CDI episodes, including ﬁrst episode and ﬁrst or second recurrence
Institution
Madrid Barcelonab Rome Naples
All
(n = 75)a
65 years
(n = 26)
>65 years
(n = 49)
All
(n = 12)
All
(n = 126)
65 years
(n = 54)
>65 years
(n = 72)
Paediatric
(n = 19)
Mean LOS, days (range)
Infected 20.6 (1–85) 23.3 (1–85) 19.2 (2–80) 42.1 (5–161) 36.0 (5–154) 39.1 (5–154) 33.7 (5–126) 7.4 (0–41)
Non-infected 11.0 (0–227) 13.8 (0–227) 8.5 (0–56) 7.9 (1–26) 18.0 (0–391) 17.0 (0–391) 19.7 (0–368) 0.3 (0–8)
Median LOS, days
Infected 13.0 12.5 13.0 26.5 29.5 27.5 29.5 5.0
Non-infected 5.5 7.0 4.0 7.5 8.0 7.0 8.0 0
Mean ICU stay, days (range)
Infected 3.4 (0–126) 1.2 (0–28) 4.5 (0–126) 7.9 (0–69) 2.1 (0–57) 2.9 (0–46) 1.4 (0–57) 0
Non-infected 0.5 (0–29) 0.8 (0–29) 0.3 (0–12) 1.3 (0–14) 0.6 (0–35) 0.3 (0–11) 1.2 (0–35) 0
Median ICU stay, days
Infected 0 0 0 0 0 0 0 0
Non-infected 0 0 0 0 0 0 0 0
Increase in LOS attributable to CDI, daysc 7.6 6.0 8.0 20.0 19.0 21.0 19.0 5.0
Mean length of isolation, days (range) 9.3 (0–53) 9.8 (0–41) 9.0 (0–53) 8.8 (0–16) 11.9 (0–52) 10.9 (0–39) 12.5 (0–52) 3.5 (0–30)
Median length of isolation, days 7.0 8.0 7.0 10.0 10 10 10 0
LOS, length of stay; CDI, Clostridium difﬁcile infection; ICU, intensive care unit.
a Number of patients refers to the infected cohort; the uninfected cohort included twice as many patients as the infected cohort.
b Not analysed by age due to small patient numbers.
c Calculated using multivariate linear regression analysis with LOS as the continuous outcome variable and based on median values.
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(Tables 4 and 5). However, it should be noted that patient numbers
for these analyses were small.
3.5. Costs attributable to CDI
The costs associated with CDI differed between sites. In Madrid,
the estimated average cost per day varied between s480.28 and
s610.58 based on 5.2% and 23.4% of the total hospital stay being in
the ICU for those patients aged 65 and >65 years, respectively.
Therefore, the attributable hospitalization costs were s4265,
s2882, and s4885 per patient for all patients and those aged 65
and >65 years, respectively. Drug costs add approximately s131
per patient (based on a total metronidazole dose of 12 958 mg and
a total vancomycin dose of 3728 mg per patient). Assuming
7601 cases per year,27 the annual cost of CDI would be
s33 413 971.Table 4
Hospital LOS for patients with a ﬁrst episode of CDI
Institution
Madrid 
All
(n = 71)a
65 years
(n = 24)
>65 year
(n = 47)
Mean LOS, days (range)
Infected 17.9 (1–80) 19.7 (1–65) 17 (2–80
Non-infected 11.3 (0–227) 14.4 (0–227) 8.6 (0–5
Median LOS, days
Infected 13.0 11.5 13.0 
Non-infected 6.0 7.0 4.0 
Mean ICU stay, days (range)
Infected 2.2 (0–57) 1.3 (0–28) 2.7 (0–5
Non-infected 0.5 (0–29) 0.8 (0–29) 0.3 (0–1
Median ICU stay, days
Infected 0 0 0 
Non-infected 0 0 0 
Increase in LOS attributable to CDI, daysc 6.4 5.0 8.0 
Mean length of isolation, days (range) 8.0 (0–33) 8.8 (0–30) 7.6 (0–3
Median length of isolation, days 7.0 8.0 7.0 
LOS, length of stay; CDI, Clostridium difﬁcile infection; ICU, intensive care unit.
a Number of patients refers to the infected cohort; the uninfected cohort included t
b Not analysed by age due to small patient numbers.
c Calculated using multivariate linear regression analysis with LOS as the continuouIn Rome, the total cost attributable to CDI was s14 023 per
patient (19.0 days  s738.06) for all patients. The cost was
s15 668 for those in the age group 65 years and s13 862 for
those aged >65 years, with the difference in cost being due to
differences in length of stay (21 vs. 19 days, respectively) and cost
per day. For subgroups aged 18–64, 65–79, and >79 years the costs
were s15 668, s16 487, and s11 112, respectively. For patients
with recurrence, the total cost attributable to CDI was s17 714 per
patient (attributable LOS 25 days), while for patients with a single
episode of CDI, the cost was s14 936. Drug costs add
approximately s51 per patient (based on a total metronidazole
dose of 6504 mg and a total vancomycin dose of 9173 mg per
patient). Based on the most recent epidemiological data for
Rome,18 this translates to an estimated cost of CDI of s32 371 per
10 000 patient-days.
For the paediatric patients in Naples, the total cost attributable
to CDI was s3545 per patient (5.0 days  s709), with drug costsBarcelonab Rome Naples
s All
(n = 10)
All
(n = 101)
65 years
(n = 61)
>65 years
(n = 40)
Paediatric
(n = 17)
) 46.0 (5–161) 34.4 (5–126) 35.3 (5–141) 33.6 (5–126) 7.7 (0–41)
6) 8.2 (1–26) 11.8 (1–59) 10.6 (1–59) 14.2 (0–62) 0.3 (0–8)
26.5 28.0 26.5 30.0 5.0
7.5 8.0 7.0 11.0 0
7) 9.5 (0–69) 2.6 (0–46) 3.3 (0–46) 1.9 (0–57) 0
2) 1.6 (0–14) 0.3 (0–8) 0.3 (0–9) 0.4 (0–8) 0
0 0 0 0 0
0 0 0 0 0
20.0 20.0 20.0 19.0 5.0
3) 8.9 (0–16) 10.1 (0–39) 10.0 (0–39) 10.2 (0–46) 3.8 (0–30)
10.0 10.0 10.0 10.0 0
wice as many patients as the infected cohort.
s outcome variable and based on median values.
Table 5
Hospital LOS for patients with one recurrent episode of CDI
Institution
Madrida Barcelonaa Romea Naples All patients
All (n = 5) All (n = 2) All (n = 23) Paediatric (n = 1) All (n = 31)
Mean LOS, days (range)
Infected 63.5 (50–77) 22.5 (15–30) 44.3 (5–154) 0.0 (0–0) 42.5 (0–154)
Non-infected 8.5 (0–23) 6.3 (2–9) 46.3 (1–391) 0.0 (0–0) 37.1 (0–391)
Median LOS, days
Infected 63.5 22.5 34.0 0.0 34.0
Non-infected 5.0 7.0 9.5 0.0 8.0
Mean ICU stay, days (range)
Infected 25.2 (0–126) 0.0 (0–0) 0.0 (0–1) 0 4.2 (0–126)
Non-infected 0.0 (0–0) 0.0 (0–0) 2.0 (0–35) 0 1.6 (0–35)
Median ICU stay, days
Infected 0 0 0 0 0
Non-infected 0 0 0 0 0
Increase in LOS attributable to CDI, daysb 45.0 NP 24.0 NP 26.0
Mean length of isolation, days (range) 19.8 (7–53) 8.5 (7–10) 17.5 (5–35) 0.0 (0–0) 16.7 (0–53)
Median length of isolation, days 11.0 8.5 18.0 0 15.0
LOS, length of stay; CDI, Clostridium difﬁcile infection; ICU, intensive care unit; NP, not possible due to small sample size.
a Not analysed by age due to small patient numbers.
b Calculated using multivariate linear regression analysis with LOS as the continuous outcome variable and based on median values.
A. Asensio et al. / International Journal of Infectious Diseases 36 (2015) e31–e38e36contributing <s100 per patient. Based on the most recent
epidemiological data for Rome, this translates to an estimated
cost of s8154 per 10 000 patient-days.
4. Discussion
This study shows that the burden of CDI in Spain and Italy in
terms of the use of hospital resources and costs, and in particular
CDI-attributable LOS, is considerable, with costs of up to s14 023
per patient. Based on data from Italy, costs appeared to be higher
for adults with recurrent disease than for those with a ﬁrst
infection (s17 714 vs. s14 936; difference of s2778), with the
majority of the cost difference likely being due to an increase in
LOS with the ﬁrst recurrence, highlighting the potential value of
preventing recurrence. In both Spain and Italy, the majority of the
CDI-associated costs in both adults and children were due to excess
hospitalization. However, the attributable LOS for adults differed
between the two countries, at 6–10 days in Spain compared to 19–
21 days in Italy. This difference resulted in a difference in costs
between the countries (s4396 per patient in Spain vs. s14 023 per
patient in Italy). Drug-related costs were relatively low and
resulted from vancomycin and metronidazole therapy. Despite
being part of treatment protocols in both countries, ﬁdaxomicin
was not used, probably because it was approved only for third-line
use in Spain, where few patients had a second recurrence, and was
approved for use in Italy only after data had been collected
(November 2013).
As in the present study, previous studies in adults have reported
varying data for attributable LOS due to CDI. A study in Spain
reported an attributable LOS of 4 days,18 with other studies in
Europe and the USA providing similar estimates.29,30 In contrast, a
literature review of European data provided estimates of up to
18 days depending on the country,22 and attributable LOS of up to
16.09 days was reported in a study in four European countries,
including Spain (13.56 days), although this study focused on
patients at increased risk of CDI.31 The reasons for these differences
are likely to include differences in patient populations, patient
history, underlying severity of disease, and comorbidities.31 Data
on some of these factors were collected in the present study for the
adult patients, and for underlying severity of disease using the
McCabe–Jackson disease classiﬁcation and Charlson comorbidity
index in particular. These data indicated that adult patients in
Spain had more severe underlying disease than those in Italy and asimilar level of comorbidity. These factors are therefore unlikely to
explain the longer attributable LOS in Italy. Similarly, the CDI
disease characteristics, although different, did not reveal any
differences that might explain the differences in attributable LOS.
One factor that could inﬂuence LOS is prior antibiotic use: the
duration of non-CDI-related antibiotic exposure has been shown to
be related to adverse outcomes.32 Unfortunately, while data on the
type and dose of antibiotic used prior to CDI diagnosis, which
appeared to differ in Spain and Italy, were collected in the present
study, no data regarding the duration of use were collected, which
would have provided greater insight. However, the use of isoniazid,
ethambutol, and rifampicin (Supplementary Material, Online
Resources 1 and 2) suggests that more patients in Italy than Spain
had tuberculosis, which may in part explain the longer LOS in Italy.
Furthermore, we did not collect information on the C. difﬁcile
serotypes implicated in CDI and it is therefore possible that
patients in Italy were more likely to be infected with hypervirulent
serotypes, which would also inﬂuence LOS.
In relation to LOS, it is also interesting to note that the median
duration of isolation of adult patients was similar in Spain and
Italy. Thus, while on average adult patients in Spain were isolated
for most or all of the CDI-attributable LOS, those in Italy were
isolated for only approximately half of their CDI-attributable LOS.
The reason for and effect of this are difﬁcult to assess, but could
also be related to the suggestion that more patients in Italy than
Spain had tuberculosis.
An additional observation in relation to LOS was that
attributable LOS with a ﬁrst recurrence was increased compared
to the initial episode in both Madrid and Rome. This conﬁrms the
burden of recurrent disease for patients with CDI and for
healthcare systems. Although the attributable LOS appeared to
be considerably higher in Madrid than in Rome, small patient
numbers mean that no conclusions should be drawn based on this.
Data on the burden of CDI in children are very limited.
Furthermore, speciﬁc considerations relating to asymptomatic
colonization and the use of diagnostic testing mean that estimates
of the incidence of CDI in paediatric patients are uncertain.33 In the
present study, the majority of cases of CDI in children occurred in
the community rather than the hospital setting. This contrasts with
the situation in adults, where hospitalization is a risk factor for CDI,
although the incidence of infections occurring in the community is
increasing.2,26,34 Furthermore, in the children included in this
study, the median CDI-attributable LOS appeared to be less than
A. Asensio et al. / International Journal of Infectious Diseases 36 (2015) e31–e38 e37that in adults in Italy (5 vs. 19 days in Rome), as did isolation and
ICU use. Therefore, although daily costs of care are higher for
children than adults, the overall burden of CDI in the paediatric
population in Italy is lower than that in adults.
As the costs of CDI in Spain and Italy are driven by the
attributable LOS, it is important to note that the methodology for
assessment in the present study differed from that used in other
studies. To account for the excess stay attributable to CDI,
comparisons of infected and non-infected patients must take into
account the potential effect of confounding factors. Matching
based on these potential confounding factors can be difﬁcult to
achieve, so it is more efﬁcient to control for them through the
analysis. In addition, the distribution of LOS was not normal. This
precluded the use of multiple linear models. For this reason, an
adjusted comparison of median LOS was performed. In line with
the data for Spain obtained in this study, a recent retrospective
cohort study found an adjusted median excess LOS attributable to
CDI of 6 days.35
Various limitations of this study can be identiﬁed. First, there
were differences in data collection and reporting between the
different institutions. Thus, the observed differences in CDI
severity between Spain and Italy could have been inﬂuenced by
data collection in the different institutions. Furthermore, cure and
recurrence were not recorded homogeneously in the available
medical records, again potentially affecting the reported rates. This
makes the assessment of factors potentially affecting cure and
recurrence rates, such as severity, treatment, or other variables,
difﬁcult.
Another limitation is the retrospective matched-cohort meth-
odology. Sources of error due to confounding and bias are more
common in retrospective studies than in prospective studies. In
addition, matching infected patients with non-infected patients by
propensity scoring may have yielded different results. Furthermore,
obtaining information from medical records could introduce bias
around the assessment of outcomes, due to potential inaccuracyand
a lack of information regarding the outcome criteria.
A further potential limitation relates to the severity of disease in
the patients studied. The hospitals participating were all tertiary
care institutions, which may have resulted in the inclusion of
patients with more severe disease than if the study had involved
other institutions. However, patient APACHE III scores (an estimate
of disease severity) were in general relatively low (mean 9.3–34.7;
maximum score of 73 on a 299-point scale). Similarly, mean scores
based on the Charlson comorbidity index, used to estimate survival
at 10 years, ranged from 2.8–6.3, with an individual maximum of
18 on a 45-point scale. These scores are indicative of patient
populations with a moderate 10-year survival prognosis. The
Charlson comorbidity index takes into account patient age; as the
mean age of patients was >65 years in Madrid and in the infected
patient cohort in Rome, the higher Charlson comorbidity index
scores and thus moderate 10-year survival prognosis in these
populations are perhaps not unexpected.
Finally, the duration of data collection ranged from 10 months–
7 years in the different study centres, with some patients treated as
early as 2006 being included. Therefore, it is possible that changes
in patient management, as well as the recent trend towards shorter
hospital stays in recent years, could have biased some of the
estimates towards estimating a longer attributable stay.
In conclusion, these data add to the evidence that the burden of
CDI, which is known to be increasing, remains considerable. The
causes of the increasing burden are two-fold: ﬁrst, the incidence
and severity are increasing, and second, the population is ageing.
As this study shows, the impact of CDI in older patients is
considerable, even though differences in cure and recurrence rates
between patient age groups were less pronounced in Spain than in
Italy, and in those with recurrent CDI. In this context, treatmentsthat can reduce LOS by reducing recurrence rates have the
potential to reduce the burden of CDI. Other solutions include
antibiotic stewardship, i.e., promoting the selection of the optimal
antibiotic drug regimen, dose, duration of therapy, and route of
administration, and infection control measures, including cleaning
and barrier precautions. Jones et al. estimated the annual cost of
CDI in Europe at s3 billion per year,36 further emphasizing that
approaches that can reduce CDI-associated resource use and costs
should be of interest. Antibiotics are a key component of therapy
for CDI, but currently represent a minimal cost in the overall
budget for CDI management. The introduction of new antibiotics
will increase drug costs; however, these agents are likely to
shorten hospital stay, reduce CDI recurrence, and reduce the time
to clinical response.37–39 Therefore, the use of new antibiotics may
be justiﬁed economically if reductions in the cost of CDI due to
shorter hospital LOS and/or fewer recurrences are demonstrated.
Furthermore, other strategies for the treatment of CDI are in
development or available: toxin-targeted monoclonal antibodies
are in development, and bacteriotherapy with probiotics and fecal
microbiota transplantation are available for third-line use after
failure of systemic drug therapy. However, the costs of these
approaches differ considerably and they therefore need to be
assessed from a pharmaco-economic perspective.
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